Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126821641 | 12682164 | 1 | I | 201604 | 20160817 | 20160824 | 20160824 | EXP | GXKR2016DE003899 | SANDOZ | 0.00 | Y | 0.00000 | 20160825 | OT | DE | DE |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126821641 | 12682164 | 1 | SS | CIPROFLOXACIN. | CIPROFLOXACIN | 1 | Oral | 500 MG, BID | N | 0 | 500 | MG | BID | ||||||
| 126821641 | 12682164 | 2 | PS | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | Oral | 600 MG, TID | 14400 | MG | N | 201692 | 600 | MG | TID | ||||
| 126821641 | 12682164 | 3 | SS | PIPERACILLIN AND TAZOBACTAM | PIPERACILLIN SODIUMTAZOBACTAM SODIUM | 1 | Intravenous (not otherwise specified) | 4.5 G, TID | N | 0 | 4.5 | G | TID | ||||||
| 126821641 | 12682164 | 4 | C | DOXYCYCLINE. | DOXYCYCLINE | 1 | Oral | 200 MG, QD | 0 | 200 | MG | QD | |||||||
| 126821641 | 12682164 | 5 | C | TRAMAL LONG | TRAMADOL | 1 | Oral | 100 MG, BID | 600 | MG | 0 | 100 | MG | BID | |||||
| 126821641 | 12682164 | 6 | C | NOVALGIN | METAMIZOLE SODIUM | 1 | Oral | 500 MG, QID | 6000 | MG | 0 | 500 | MG | QID | |||||
| 126821641 | 12682164 | 7 | C | PANTOZOL | PANTOPRAZOLE SODIUM | 1 | Oral | 40 MG, QD | 0 | 40 | MG | QD | |||||||
| 126821641 | 12682164 | 8 | C | MONO-EMBOLEX | CERTOPARIN SODIUM | 1 | Subcutaneous | 3000 IU, QD | 9000 | IU | 0 | 3000 | IU | QD | |||||
| 126821641 | 12682164 | 9 | C | CLINDAMYCIN | CLINDAMYCINCLINDAMYCIN PHOSPHATE | 1 | Oral | 600 MG, TID | 0 | 600 | MG | TID |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126821641 | 12682164 | 1 | Osteitis |
| 126821641 | 12682164 | 2 | Osteitis |
| 126821641 | 12682164 | 3 | Osteitis |
| 126821641 | 12682164 | 4 | Osteitis |
| 126821641 | 12682164 | 5 | Pain |
| 126821641 | 12682164 | 6 | Pain |
| 126821641 | 12682164 | 7 | Gastritis |
| 126821641 | 12682164 | 8 | Thrombosis prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126821641 | 12682164 | DS |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126821641 | 12682164 | Epicondylitis | |
| 126821641 | 12682164 | Sensory loss | |
| 126821641 | 12682164 | Tendon pain |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126821641 | 12682164 | 1 | 20160402 | 20160419 | 0 | |
| 126821641 | 12682164 | 2 | 20160325 | 20160402 | 0 | |
| 126821641 | 12682164 | 3 | 20160402 | 20160407 | 0 | |
| 126821641 | 12682164 | 4 | 20160408 | 201605 | 0 | |
| 126821641 | 12682164 | 5 | 20160330 | 20160423 | 0 | |
| 126821641 | 12682164 | 6 | 20160330 | 201605 | 0 | |
| 126821641 | 12682164 | 7 | 20160416 | 20160423 | 0 | |
| 126821641 | 12682164 | 8 | 20160330 | 201605 | 0 | |
| 126821641 | 12682164 | 9 | 20160412 | 20160419 | 0 |